

**Stephen A. Adamu, MS., MBA., EdD**  
 3532 Bear Creek Court, Newbury Park, CA 91320  
 (805) 376-8145 (home), (805) 236-3189 (cell), steveadamu@gmail.com

*Academic Professional at the Intersection of Science and Business*

## **CAREER SUMMARY**

Versatility in the biopharmaceutical industry with demonstrated ability to complete projects successfully. I have 16 years of University/Academic experience at University of California at Los Angeles. I acquired 11 years of Biotechnology/Biopharmaceutical industry research experience at Amgen where I participated on a successful osteoporosis project in which I provided scientific support in discovery research through to the FDA filing. This comprehension of the life-cycle of a product provides a solid foundation to analyze and efficiently communicate cross-functionally and across broad audiences. I have 2 years of experience as a teaching assistant at University of Rhode Island, Kingston Rhode Island.

## **EDUCATION**

**EdD** – Doctor of Education in Organizational Leadership, Pepperdine University, Graduate School of Education and Psychology, Los Angeles, CA May 2017

**Dissertation topic** – Impact of Corporate Social Responsibility on Financial Performance in the Pharmaceutical Industry

**Comprehensive Exam topic** – Maximizing Organizational Potential of a Pharmaceutical Company: A Strategic Business Initiative to Improve Genmapp

**MBA** – Master of Business Administration, Pepperdine University, Malibu, California 2002

**MS** – Master of Science in Pathogenic Microbiology, University of Rhode Island, Kingston, Rhode Island 1980

**BS** – Bachelor of Science in Zoology, Ohio University, Athens, Ohio 1975

## **CORPORATE EXPERIENCE**

**Senior Associate Scientist, Amgen Inc., Thousand Oaks, CA.,** Metabolic Disorders Research 2001 – 2007

- Provided scientific support for a therapeutic compound, the AMG 162 (Amgen's Prolia®/XGEVA™, denosumab approved by the FDA in 2010 for treatment of osteoporosis in postmenopausal women (Prolia®) and for the prevention of skeletal-related events in patients with bone metastases from solid tumors (XGEVA™)
- Collaborated with AMG 162 cross-functional team within the company as well as with external investigators
- Expert in Bone and Osteoporosis Research with an emphasis on developing novel assays for monitoring biochemical markers of bone turnover [e.g., Osteoclast-derived Tartrate-resistant acid Phosphatase, isoform 5b (TRAP-5b), osteocalcin, an osteoblast-specific formation marker, and bone-specific alkaline phosphatase].
- Organized and conducted training of co-workers on bone biochemical marker assays for evaluating pre-clinical drugs, in support of the Discovery Research group in the Metabolic Disorders Research department.

- Collected, analyzed, reviewed, interpreted and presented data in the form of both written and oral reports, and assisted in the preparation of manuscripts for scientific publications and annual conferences/meetings

**Research Associate II / III, Amgen Inc., Thousand Oaks, CA.,** Department of Pathology/ Pharmacology 1996 – 2001

- Developed and formulated a novel Leptin analog, dextran-leptin conjugate, a therapeutic compound for weight loss that became a clinical drug candidate in Amgen.
- Co-designed and implemented the *in vivo* and *in vitro* studies that evaluated leptin and leptin back-up compounds
- Successfully organized the transfer of the production methodology of a drug candidate, to the Process Team in Process Development department, for large-scale production for clinical studies.
- Processed and presented data at both inter and intra- departmental meetings

#### UNIVERSITY/ACADEMIC EXPERIENCE

**Staff Research Associate II University of California at Los Angeles,** Department of Ophthalmology, Jules Stein Eye Institute 1986 – 1996

- Developed a significant NIH research grant with principal investigator at Jules Stein's Corneal External Disease Division (JSCEDD) in University of California at Los Angeles. Acted as liaison to principal investigator in grants and manuscripts preparation and management. Conferred with Principal Investigator to discuss all funding issues, including possible disallowances, projected overdrafts as well as interpreting departmental and University policies.
- Independently extracted and purified bacteria cell wall antigens and endotoxin used for the animal studies in JSCEDD laboratories
- Developed, monitored, and implemented animal models of blepharitis, corneal phlyctenulosis, catarrhal infiltrates, and bacterial endophthalmitis
- Facilitated and managed the timelines of research studies by the Ophthalmology Fellows and Residents in JSCEDD labs, including designing, and execution of research studies in ophthalmology based on current state of the art knowledge of ophthalmology literature and research
- Supervised laboratory technicians and synchronized workflow of co-workers to assist in the completion of scientific experiments and coordinated purchase requisitions and hiring of laboratory helpers
- Collected, organized, performed statistical analyses and interpreted data for scientific publications

**Staff Research Associate II University of California at Los Angeles,** Department of Medicine, Division of Infectious Diseases 1980 –1985

- Coordinated animal studies of bacterial infection using monoclonal antibody as prophylaxis for gram-negative bacterial challenge
- Assessed the opsonic requirements for various serologically identified E. coli using Luminol-dependent chemiluminescence

- Extracted and purified bacteria cell wall antigens. Generated, purified and characterized monoclonal antibodies to the bacterial proteins
- Presented research findings and abstracts at international scientific meetings
- Regularly attended professional meetings and training (e.g. Interscience Conference of Antimicrobial Agents and Chemotherapy)

**Teaching Assistant University of Rhode Island at Kingston, Rhode Island,**  
Department of Microbiology 1978 – 1980

- Taught undergraduate microbiology courses and assisted my major professor in conducting undergraduate microbiology labs and in grading the lab examinations.

## **PUBLICATIONS:**

- Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, **Adamu S**, Ke HZ, Simonet WS, Kostenuik PJ. Increased RANK ligand in bone marrow of orchietomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. *Bone* 45(4): 669-76, 2009.
- Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, **Adamu S**, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. *Journal of Bone & Mineral Research* 24(7): 1234-46, 2009.
- Yuan YY, Kostenuik PJ, Ominsky MS, Morony S, **Adamu S**, Simionescu DT, Basalyga DM, Asuncion FJ, Bateman TA. Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. *Osteoporosis International*. 19(5): 625-35, 2008.
- Kostenuik PJ, Ferrari S, Pierroz D, Bouxsein M, Morony S, Warmington KS, **Adamu S**, Geng Z, Grisanti M, Shalhoub V, Martin S, Biddlecome G, Shimamoto G, Boone T, Shen V, Lacey D. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone. *Journal of Bone & Mineral Research* 22(10): 1534-47, 2007.
- Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, **Adamu S**, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Ke HZ, Li X, Richards WG. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia, *Bone* 39: 754-766, 2006.
- Marina Stolina, **Stephen Adamu**, Mike Ominsky, Denise Dwyer, Frank Asuncion, Zhaopo Geng, Scot Middleton, Heather Brown, Jim Pretorius, Georg Schett, Brad Bolon, Ulrich Feige, Debra Zack, and Paul J Kostenuik. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. *J Bone and Mineral Research* 20: 1756-1765, 2005.
- Sean Morony, Kelly Warmington, **Stephen Adamu**, Frank Asuncion, Zhaopo Geng, Mario Grisanti, Hong Lin Tan, Casey Capparelli, Charlie Starnes, Bernadette Weimann, Colin R. Dunstan, and Paul J. Kostenuik: The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. *Endocrinology* 146(8): 3235–3243, 2005.

- Bo Abrahamsen, Jacob vB Hjelmberg, Paul Kostenuik, Lis S Stilgren, Kirsten Kyvik, **Stephen Adamu**, Kim Brixen, Bente L Langdahl. Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins: Heritability of OPG and RANKL in twins. *Bone* 36: 727– 735, 2005.
- F R Byrne, S Morony, K Warmington, Z Geng, H L Brown, S A Flores, M Fiorino, S L Yin, D Hill, V Porkess, D Duryea, J K Pretorius, **S Adamu**, R Manuokian, D M Danilenko, I Sarosi, D L Lacey, P J Kostenuik, G Senaldi CD4+CD45RB<sup>hi</sup> T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin  
*Gut* 2005; 54: 78–86.
- Charles Capparelli, Sean Morony, Kelly Warmington, **Stephen Adamu**, David Lacey, Colin R. Dunstan, Brian Stouch, Steven Martin, and Paul. J. Kostenuik. Sustained antiresorptive effects after a single treatment with human recombinant Osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats. *J Bone and Mineral Research* 18: 852-858, 2003.
- Paul. J. Kostenuik, Casey Capparelli, Sean Morony, **Stephen A. Adamu**, Grant Shimamoto, Victor Shen, David L. Lacey, and Colin R. Dunstan. OPG and PTH- (1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. *Endocrinology* 142(10): 4295-4304, 2001.
- Giese MJ, **Adamu SA**, Pitcheikian-Halabi H, Ravindranath RMH, Mondino BJ: The effect of Staphylococcus aureus Phage Lysate vaccine on a rabbit model of staphylococcal blepharitis, phlyctenulosis and catarrhal infiltrates. *Am. J. Ophthalmol.* 122:245-254, 1996.
- Ravindranath RMH, Mondino BJ, **Adamu SA**, Pitcheikian-Halabi H, Hasan SA, Glasgow BJ: Immunopathological features of Staphylococcus aureus endophthalmitis in the rat. *Invest. Ophthalmol. Vis. Sci.* 36:2482-2491, 1995.
- Giese MJ, Mondino BJ, Glasgow BJ, Sumner H, **Adamu SA**, Pitcheikian-Halabi H, Chou HJ: The complement system and host defense against staphylococcal endophthalmitis. *Invest. Ophthalmol. Vis. Sci.* 35:1026-1032, 1994.
- Milani JK, Verbukh I, Pleyer U, Sumner H, **Adamu SA**, Pitcheikian-Halabi H, Chou HJ, Lee DA, Mondino BJ: Collagen Shields impregnated with gentamicin-dexamethasone as a potential drug delivery device. *Am J Ophthalmol* 116:622-627, 1993.
- Pleyer U, Mondino BJ, **Adamu SA**, Pitcheikian-Halabi H, Engstrom RE, Glasgow BJ: Immune response to Staphylococcus epidermidis-induced endophthalmitis in a rabbit model. *Invest. Ophthalmol. Vis. Sci.* 33:2650-2663, 1992.
- Mondino BJ, **Adamu SA**, Pitcheikian-Halabi H: Antibody studies in a rabbit model of the corneal phlyctenulosis and catarrhal infiltrates related to Staphylococcus aureus. *Invest. Ophthalmol. Vis. Sci.* 32:1854-1863, 1991.
- Engstrom RE, Mondino BJ, Glasgow BJ, Pitcheikian-Halabi H, **Adamu SA**: Immune response to Staphylococcus aureus endophthalmitis in a rabbit model. *Invest. Ophthalmol. Vis. Sci.* 32:1523-1533, 1991.
- Mondino BJ, **Adamu SA**: Ocular immune response to Staphylococcus epidermidis. In: *The Cornea: Transactions of the World Congress on the Cornea III.* (Ed.) Cavanaugh HD. Raven Press, Ltd. New York, 1988, pp. 431-433.

- Mondino BJ, Brawman-Mintzer O, Adamu SA: Corneal antibody levels to ribitol teichoic acid in rabbits immunized with staphylococcal antigens using various routes. Invest. Ophthalmol. Vis. Sci. 28:1553-1558, 1987.
- Mondino BJ, Laheji K, Adamu SA: Ocular Immunity to Staphylococcus aureus. Invest. Ophthalmol. Vis. Sci. 28:560-564, 1987.
- Stevens P, Young LS, Adamu SA, 1983. Opsonization of various capsular (K) E. coli by the alternative complement pathway. Immunology 50:497-502.
- Adamu SA, Sperry JF, 1981. Polymorphonuclear neutrophil chemotaxis induced and inhibited by Bacteroides fragilis. Infect Immune 33:806-810.

### ABSTRACTS & PRESENTATIONS:

- Ominsky MS, Corbin T, Stolina M, Dwyer D, Li X, Morony S, Warmington KS, Geng Z, Grisanti M, Tan H, Adamu S, Asuncion F, Bolon B, McCabe J, Kostenuik PJ. Serum OPG levels are correlated positively with bone strength and inversely with bone turnover in mature OPG transgenic rats. Calc Tiss Int 78 (S1): OC032, 2006.
- Ominsky MS, Corbin TJ, Stolina M, Dwyer D, Li X, Morony S, Warmington KS, Geng Z, Grisanti M, Tan H, Adamu S, Asuncion F, Bolon B, McCabe J, Kostenuik PJ, Bone strength is inversely related to bone turnover in mature transgenic rats overexpressing the RANKL inhibitor OPG, Osteoporosis Intl 17 (S2): OC11 (S9-10), 2006.
- Li X, Asuncion F, Ominsky MS, Adamu S, Dwyer D, Stolina M, Tan HL, Grisanti M, Warmington KS, Kostenuik PJ, RANKL Inhibition with OPG preserves bone density and trabecular architecture in ovariectomized rats, J Bone Min Res 21 (S1): SU386, 2006.
- M. Stolina, S. Adamu, D. Dwyer, S. Middleton, F. Asuncion, M. Ominsky, G. Schett, U. Feige, P. Kostenuik, D. J. Zack. RANKL inhibition with Osteoprotegerin (OPG) prevents bone loss but does not affect immune status in arthritic rats. J Bone Min Res 20 (Suppl. 1): S257, 2005.
- Li X, Capparelli C, Morony S, Adamu S, Asuncion F, Hoffman K, Grisanti M, Tan HL, and Kostenuik PJ. The RANKL inhibitor osteoprotegerin causes rapid and significant increases in bone density in rats co-treated with parathyroid hormone. Bone 36 (Suppl. 2): S299, 2005.
- P. J. Kostenuik, K. Warmington, M. Grisanti, S. Morony, Z. Geng, H. L. Tan, C. Christensen, J. Sullivan, H. Nguyen, S. Adamu, F. Asuncion, M. Ominsky, X. Li, J. McCabe. RANKL inhibition with AMG 162, a fully human mAb, causes sustained suppression of bone resorption and increased BMD in knockin mice expressing humanized RANKL. J Bone Min Res 20 (Suppl. 1): SU304, 2005.
- Stolina M, Middleton S, Adamu S, Asuncion F, Geng Z, Ominsky M, Zack D, McDormand K and Kostenuik P. 2005 The RANKL inhibitor osteoprotegerin (OPG) prevents focal bone erosions in adjuvant arthritic rats without inducing renal pathology: A comparison with zoledronic acid. EULAR 2005, Ann Rheum Dis 64:441.
- Y. Y. Yuan, A. G. Lau, P. J. Kostenuik, S. Morony, S. Adamu, F. Asuncion, T. A. Bateman. Soluble RANKL Has Detrimental Effects on Cortical and Trabecular Bone Volume, Mineralization and Bone Strength in Mice. J Bone Min Res 20 (Suppl. 1): S161-162, 2005.

- P. J. Kostenuik, F. Asuncion\*, K. Warmington\*, S. Morony, H. Tan, M. Grisanti\*, **S. Adamu**. Metabolic Disorders, Amgen, Inc., Thousand Oaks, CA, USA. Coupling of bone resorption and bone formation: A comparison of a RANKL antagonist (OPG) and bisphosphonates in mice. ASBMR 2004 Abstract # M300.
- J. Li, I. Sarosi\*, S. E. Morony, D. Hill\*, Y. Wang\*, W. Qiu\*, **S. Adamu\***, M. Grisanti\*, K. Hoffmann\*, T. Gyuris\*, H. Nguyen\*, R. Cattley\*, P. J. Kostenuik, S. S. Simonet, D. L. Lacey. Amgen Inc., Thousand Oaks, CA, USA. Transgenic Mice Over-Expressing Dkk-1 in Osteoblasts Develop Osteoporosis. ASBMR 2004 Abstract # 1017.
- Stolina M, Schett G, Bolon B, Middleton S, Brown H, Zhu L, **Adamu S**, Asuncion F, Kostenuik P, Feige U, Zack D, Bone loss in inflammatory arthritis is associated with a local and systemic decrease in parameters of bone formation, J Bone Min Res 19 (S1): M272, 2004.
- Kostenuik PJ, Stolina M, Bolon B, **Adamu S**, Asuncion F, Morony S, Schett G, Middleton S, Feige U, Zack D, RANKL and TRAP-5b are markers of bone destruction in two rat models of inflammatory arthritis, J Bone Min Res 19 (S1): SA510, 2004.
- Kostenuik PJ, Asuncion F, Warmington K, Morony S, Tan H, Grinsanti M, **Adamu S**, Coupling of bone resorption and bone formation: A comparison of a RANKL antagonist (OPG) and bisphosphonates in mice, J Bone Min Res 19 (S1): M300, 2004.
- Milani JK, Verbukh I, Pleyer U, Sumner H, **Adamu SA**, Pitcheikian-Halabi H, Chou HJ, Lee DA, Mondino BJ. Collagen shields impregnated with a gentamicin-dexamethasone combination as a potential drug delivery device after intraocular surgery. Invest. Ophthalmol. Vis. Sci. (ARVO supp.) 855, 1993.
- Mondino BJ, Giese MJ, Sumner H, **Adamu SA**, Pitcheikian-Halabi H, Chou HJ. The complement system and host defense against Staphylococcus aureus endophthalmitis. Invest. Ophthalmol. Vis. Sci. (ARVO supp.) 1258, 1993.
- Giese MJ, Mondino BJ, Sumner H, **Adamu SA**, Pitcheikian-Halabi H, Chou HJ. The complement system and host defense against Staphylococcus epidermidis endophthalmitis. Invest. Ophthalmol. Vis. Sci. (ARVO supp.) 919, 1993.
- Engstrom RE, Mondino BJ, Pitcheikian-Halabi H, **Adamu SA**. Immune response in Staphylococcus aureus endophthalmitis. Invest. Ophthalmol. Vis. Sci. 31 (ARVO supp.) 450, 1990.
- Gascon R, **Adamu SA**, Bermudez L, Lancero M, Young LS, 1985. Functional activity of monoclonal antibody against common core lipopolysaccharide antigen of P. aeruginosa. 24th Interscience Conference of Antimicrobial Agents and Chemotherapy. Minnesota, September 1985.
- Hong D, **Adamu SA**, Stevens P, 1984. Monoclonal antibodies to a protein of Candida albicans. 23rd Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington D.C., October 1984.
- Adamu SA**, Stevens P, Young LS, 1982. E. coli K5 capsular antigen prevalence and mechanism of resistance to phagocytosis. 22nd Interscience Conference of Antimicrobial Agents and Chemotherapy. Miami, Fla., October 1982.
- Stevens P, Young LS, **Adamu SA**, 1981. Serum Opsonic requirements for various capsular (K) serotypes of E. coli. 21st Interscience conference on Antimicrobial Agents and Chemotherapy. Chicago, III. November 1981.

**ADDITIONAL EXPERIENCE/SELF EMPLOYMENT:****2008 – 2013 Independent Financial Trader**

- High Probability Trading using advanced stocks/options strategies to trade independently in up, down and sideways markets. Utilized PC based technical analysis software systems to analyze stocks/options and identify appropriate entry and exit strategies.

**2008 – 2012 Real Estate Professional/Entrepreneur**

- Established a solid professional business network with local/national network of real estate agents, buyers and sellers, mortgage officers, title personnel and attorneys involved in the home buying and selling process
- Purchased and co-managed multiple rental properties in the greater Los Angeles, Las Vegas, and Atlanta metropolitan regions.

**PROFESSIONAL CERTIFICATION:**

Studied Global Enterprise Management at two universities in the European Union to gain an international perspective on business needed to compete successfully in the global marketplace;

- **University of Oxford (United Kingdom)** – Global Enterprise Management Organization, Environmental and Political Economy. Earned a certificate in Organization, Environmental, and Political Economy. 2002
- **University of Antwerp (UFSIA) (The Netherlands)** – Business in a European Context. Earned a certificate in Business in a European Context 2002
- Clinical Laboratory Scientist, License # MTA 35854, State of California 1992

**PROFESSIONAL AWARDS:**

- University Of Rhode Island, Chapter of the Society of Sigma Xi Award in Biological Sciences for the Best Masters Thesis of the Year: “Correlation of in vitro chemotaxis with in vivo virulence of Bacteroides fragilis products”
- Tuition Scholarship, University of Rhode Island Graduate School
- Tuition Scholarship, Ohio University; Athens, Ohio

**MEMBERSHIPS AND SOCIETIES:**

- American Society of Bone and Mineral Research
- American Society for Microbiology
- California Association for Medical Laboratory Technology